Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
November 5, 2018
Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
BOSTON and LONDON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious ...
November 5, 2018
UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018
RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (URGN) today announced that it will report third quarter 2018 financial results on Monday, November 12, 2018, ...
November 5, 2018
Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update
PITTSBURGH, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported ...
November 5, 2018
Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
HOPKINTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
November 5, 2018
Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH
SALT LAKE CITY, Nov. 5, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the proof-of-concept clinical study ...
November 5, 2018
AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
November 5, 2018
BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has received the second installment payment ...
November 5, 2018
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
SANTA MONICA, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, ...
November 5, 2018
Tyme Provides Clinical and Corporate Update for Fiscal 2Q 2019
NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and ...
November 5, 2018
CohBar Provides Update on CB4211 Clinical Trial
MENLO PARK, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
November 5, 2018
Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
November 5, 2018
Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer
WATERTOWN, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical stage leader in the field of stabilized, cell-permeating peptides to treat cancer ...
November 1, 2018
AC Immune to Present at 2018 Society for Neurosciences Meeting
Lausanne, Switzerland, November 1, 2018 - AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases will provide ...
November 1, 2018
Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it is scheduled to present at the following upcoming events: BIT’s 16th Annual Congress of International ...
November 1, 2018
AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
November 1, 2018
Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
HOPKINTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
November 1, 2018
Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8
EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
November 1, 2018
MannKind Corporation Reports 2018 Third Quarter Financial Results
WESTLAKE VILLAGE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today reported financial results for the third quarter ended September 30, 2018. ...
November 1, 2018
Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced operating and financial results for the third quarter ending ...
November 1, 2018
Aimmune Therapeutics to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in ...
Page 7 of 117